EUVIMEDSkopri EUVIMED
Open access · CC BY-NC 4.0

Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model

Le Ying iD, Phoebe Liu, Zhoujie Ding iD, Georgie Wray-McCann, Jack Emery, Nina Colon, Lena Hm Le, Le Son Tran iD, Ping Xu, Liang Yu, Dana J Philpott iD, Yugang Tu and 5 more

The Journal of Pathology · 2023

DOI: 10.1002/path.6053 ↗

At a glance

Journal article in The Journal of Pathology, 2023. Written by Le Ying and 16 co-authors. Institution: Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia. Major MEDLINE topics: Stomach Neoplasms, Helicobacter Infections, Helicobacter pylori, Lymphoma, B-Cell, Marginal Zone. Cited 5 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Health and Medical Research Council, National Medical Research Council, Tanoto Foundation.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Mucosa‐associated lymphoid tissue (MALT) lymphoma is a B‐cell tumour that develops over many decades in the stomachs of individuals with chronic Helicobacter pylori infection. We developed a new mouse model of human gastric MALT lymphoma in which mice with a myeloid‐specific deletion of the innate immune molecule, Nlrc5, develop precursor B‐cell lesions to MALT lymphoma at only 3 months post‐ Helicobacter infection versus 9–24 months in existing models. The gastric B‐cell lesions in the Nlrc5 knockout mice had the histopathological features of the human disease, notably lymphoepithelial‐like lesions, centrocyte‐like cells, and were infiltrated by dendritic cells (DCs), macrophages, and T‐cells (CD4 + , CD8 + and Foxp3 + ). Mouse and human gastric tissues contained immune cells expressing immune checkpoint receptor programmed death 1 (PD‐1) and its ligand PD‐L1, indicating an immunosuppressive tissue microenvironment. We next determined whether CD40L, overexpressed in a range of B‐cell malignancies, may be a potential drug target for the treatment of gastric MALT lymphoma. Importantly, we showed that the administration of anti‐CD40L antibody either coincident with or after establishment of Helicobacter infection prevented gastric B‐cell lesions in mice, when compared with the control antibody treatment. Mice administered the CD40L antibody also had significantly reduced numbers of gastric DCs, CD8 + and Foxp3 + T‐cells, as well as decreased gastric expression of B‐cell lymphoma genes. These findings validate the potential of CD40L as a therapeutic target in the treatment of human gastric B‐cell MALT lymphoma. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Stomach NeoplasmsHelicobacter InfectionsHelicobacter pyloriLymphoma, B-Cell, Marginal ZoneB-LymphocytesTumor MicroenvironmentLymphoma, Non-HodgkinForkhead Transcription FactorsIntracellular Signaling Peptides and ProteinsMiceAnimalsCD40 Ligand

Author keywords

APRILB-cellBAFFCD40 ligandHelicobacterMALT lymphomaNLRC5PD-L1multiplex immunohistochemistry

Substances

CD40 LigandForkhead Transcription FactorsIntracellular Signaling Peptides and ProteinsNLRC5 protein, humanNLRC5 protein, mouse

Authors and institutions

  • Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, VIC, Australia.
  • Department of Molecular and Translational Science, Monash University, Clayton, VIC, Australia.
  • Department of Immunology, University of Toronto, Toronto, ON, Canada.
  • Department of Immunology and Pathology, Central Clinical School, Monash University, Clayton, VIC, Australia.
  • Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Solna, Sweden.
  • Department of Tea Science, Zhejiang University, Hangzhou, PR China.

ORCID profiles: Le Ying, Zhoujie Ding, Le Son Tran, Dana J Philpott, Choon K Ong, Richard L Ferrero

Funding

  • National Health and Medical Research Council
  • National Medical Research Council
  • Tanoto Foundation
  • U.S. Department of Defense
  • Public Health Agency of Canada

Cite

APA

Ying, L., Liu, P., Ding, Z., Wray-McCann, G., Emery, J., Colon, N., Le, L. H., Tran, L. S., Xu, P., Yu, L., Philpott, D. J., Tu, Y., Cheah, D. M., Cheng, C. L., Lim, S. T., Ong, C. K., & Ferrero, R. L. (2023). Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model. The Journal of Pathology. https://doi.org/10.1002/path.6053

Vancouver

Ying L, Liu P, Ding Z, Wray-McCann G, Emery J, Colon N, et al. Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model. The Journal of Pathology. 2023. doi:10.1002/path.6053

BibTeX
@article{Ying2023,
  author = {Ying, Le and Liu, Phoebe and Ding, Zhoujie and Wray-McCann, Georgie and Emery, Jack and Colon, Nina and Le, Lena Hm and Tran, Le Son and Xu, Ping and Yu, Liang and Philpott, Dana J and Tu, Yugang and Cheah, Daryl Mz and Cheng, Chee L and Lim, Soon T and Ong, Choon K and Ferrero, Richard L},
  title = {Anti‐CD40L therapy prevents the formation of precursor lesions to gastric B‐cell MALT lymphoma in a mouse model},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6053}
}
Start for free →